Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press82010.36691/RJA820ArticlesСтатьиТHE EFFICIENCY AND SAFETY OF CALCINEURIN INHIBITORS (TACROLIMUS) IN ATOPIC DERMATITIS AND OTHER DERMATOLOGICAL DISEASESЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬПРИМЕНЕНИЯ ИНГИБИТОРОВКАЛЬЦЕНЕВРИНА (ТАКРОЛИМУСА) ПРИ АТОПИЧЕСКОМ ДЕРМАТИТЕ И ДРУГИХ ЗАБОЛЕВАНИЯХ КОЖИOchelenkoS AОчеленкоС А

Кафедра дерматовенерологии с клиникой; Санкт-Петербургский медицинский университет им. акад. И.П. Павлова

ochelenko-v@yandex.ruMonakhovK NМонаховК Н

Кафедра дерматовенерологии с клиникой; Санкт-Петербургский медицинский университет им. акад. И.П. Павлова

OchelenkoS A

Рavlov State Мedical University of St .Petersburg

MonakhovK N

Рavlov State Мedical University of St .Petersburg

Санкт-Петербургский медицинский университет им. акад. И.П. ПавловаРavlov State Мedical University of St .Petersburg1504201182NO2 (2011)№2 (2011)899510032020Copyright ©; 2011, Pharmarus Print MediaCopyright ©; 2011, Фармарус Принт Медиа2011Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/820

The problems of clinical efficiency and safety of application of tacrolimus (Protopik) at various skin diseases are discussed in this review. High efficiency of this drug, allows to use it in treatment of different dermatosis. The clinical effect is comparable with topical corticosteroids, and the rate of adverse effects is lower. It is possible to use long applications of calcineurin inhibitors in patients with resistant forms of atopic dermatitis. Positive effects of application of tacrolimus in vitiligo, balanitis, alopecia areata etc. are described.

В обзоре обсуждается клиническая эффективность и безопасность применения такролимуса при различных заболеваниях кожи. Высокая эффективность препарата позволяет использовать его для лечения различных дерматозов. Получаемый при этом клинический эффект сравним с результатами терапии топическими кортикостероидами, а наличие свойственных для кортикостероидов побочных эффектов нехарактерно. Возможно длительное применение ингибиторов кальциневрина у пациентов с резистентными формами атопического дерматита, особенно в области лица и шеи. Имеются сообщения о положительных эффектах применения такролимуса при таких заболеваниях, как: витилиго, кожные формы красной волчанки, баланит, гнездная алопеция, липоидный некробиоз.

Calcineurin InhibitorsTacrolimusAtopic DermatitisLupus erythematosusVitiligoAlipecia areataингибиторы кальциневринатакролимусатопический дерматиткрасная волчанкавитилигокруговидное облысениеКочергин Н.Г. и соавт. Пимекролимус при атопическом дерматите. Рос. журн. кож. и вен. болезней. 2003, № 6, с. 7-12.Sulzberger M.B., Witten V.H. The effect of topically applied compound F in selected dermatoses. J. Invest. Dermatol. 1952, v. 19, p. 101-102.Hengge U.R., Ruzicka T, Schwartz R.A., Cork M.J. Adverse effects of topical glucocorticosteroids. J. Am. Acad. Dermatol. 2006, v. 54 (1), p. 1-15.Giusti F., Martella A., Bertoni L., Seidenari S. Skin barrier, Hydration, and PH of the skin of Infants Under 2 years of Age. Ped. Derm. 2001, v. 18, p. 93-96.Walsh P., Aeling G.L., Huff L., Weston WL. Hypotalamuspituitary-adrenal axis suppression by superpotent steroids. J. Am. Acad. Dermatol. 1993, v. 29, p. 501-503.Корсунская И.М., Дворянкова Е.В. Новые препараты в местной терапии атопического дерматита. Consilium Medicum. 2004, № 3, с. 4-9.Liu J., Farmer J.D. Jr., Lane WS. et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991, v. 66, p. 807-815.Stuetz A., Grassberg M., Meingasser J.G. Pimecrolimus (Elidel, SDZ ASM 981)-preclinical pharmacologic profile and skin selectivity. Semin. Cutan. Med. Surg. 2001, v. 20 (4), p. 233-241.Darren M. Ashcroft, Paul Dimmock, Ruth Garside, Ken Stein, Hywel C. Williams. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials . BMJ. 2005, v. 330, p. 516.Williams H., Robertson C., Stewart A. et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood. J. Allergy Clin. Immunol. 1999, v. 103, p. 125-138.Laughter D., Istvan J.A., Tofte S.J., Hanifin J.M. The prevalence of atopic dermatitis in Oregon schoolchildren. J. Am. Acad. Dermatol. 2000, v. 43, p. 649-655.Jennifer D. Peterson, MD, Lawrence S. Chan, MD. A Comprehensive Management Guide for Atopic Dermatitis. Dermatol. Nurs. 2006, v. 18 (6), p. 531-542.Ashcroft D.M., Chen L.C., Garside R. et al. Topical pimecrolimus for eczema. Cochrane Database of Systematic Reviews. 2007, Issue 4.Fleischer A.B. Jr, Abramovits W., Breneman D., Jaracz E. US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. J. Dermatolog. Treat. 2007, v. 18 (3), p. 151-157.Reitamo S., Ortonne J.P., Sand S. et al. A multicentre, randomized, doublr-blind, controlled study of long-term treatment with 0,1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br. J. of Dermatology. 2005, v. 152, p. 1282-1289.Hebert A.A. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis. Department of Dermatology, The University of Texas Health Science Center, Houston, Texas 77030, USA.Kalthoff F., Meingassner J.G., Chung J. et al. Pimecrolimus and tacrolimus differ in their inhibition of lymphocyte activation during the sensitization phase of contact hypersensitivity.J. Dermatol. Sci. 2006, v. 43 (2), p. 117-126.Kyllonen H., Remitz A., Mandelin J.M. et al. Effects of 1-year intermittend treatment with topical tacrolimus monotherapy on skin collagen synthesis in patient with atopic dermatitis. Br. J. of Dermatology. 2004, v. 150, p. 1174-1181.Reuters Health Information 2006. Pimecrolimus Cream Provides Fast Relief of Pruritus. Allergy. 2006, v. 61, p. 375-381.Sheng-Li Chen. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: A meta-analysis of randomized clinical trials. Journal of Dermatological Treatment. 2010, v. 21, p. 144-156.Reitamo S. et al. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies. Journal of Dermatological Treatment. 2010, v. 21, p. 34-44.Lebwohl M., Freeman A.K., Chapman M.S et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. Acad. Dermatol. 2004, v. 51 (5), p. 723-730. Arch. Dermatol. 2005, v. 141 (9), p. 1152-1153.Clayton T.H., Harrison P.V., Nicholls R., Delap M. Topical tacrolimus for facial psoriasis. Br. J. Dermatol. 2003, v. 49, p. 419-420.Yamamoto T, Nishioka K. Topical tacrolimus is effective for facial lesions of psoriasis. Acta. Derm. Venereol. 2000, v. 80, p. 451.Nagao K., Ishiko A., Yokoyama T et al. A case of generalized pustular psoriasis treated with topical tacrolimus. Arch. Dermatol. 2003, v. 139, p. 1219.Wilsmann-Theis D., Hagemann T, Dederer H. et al. Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0,1% ointment. Br. J. Dermatol. 2004, v. 150, p. 1194-1197.Kreuter A., Sommer A., Hyun J. et al. 1% pimecrolimus, 0,005% calcipotriol, and 0,1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch. Dermatol. 2006, v. 142 (9), p. 1138-1143.Gottlieb A.B., Griffiths C.E., Ho V.C. et al. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br. J. Dermatol. 2005, v. 152 (6), p. 1219-1227.Swift J.C., Rees T.D., Plemons J.M. et al. The effectiveness of 1 % pimecrolimus cream in the treatment of oral erosive lichen planus. J. Periodontol. 2005, v. 76 (4), p. 627-635.Passeron T., Lacour J.P., Fontas E., Ortonne J.P. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch. Dermatol. 2007, v. 143 (4), p. 519-523.Braza T.J., DiCarlo J.B., Soon S.L., McCall C.O. Tacrolimus 0,1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br. J. Dermatol. 2003, v. 148, p. 1242-1244.Meshkinpour A., Sun J., Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J. Am. Acad. Dermatol. 2003, v. 49, p. 145-147.Rigopoulos D., Ioannides D., Kalogeromitros D. et al. Treatment of Seborrhoeic Dermatitis. Br. J. Dermatol. 2004, v. 151 (5), p. 1071-1075.Meshkinpour A., Sun J., Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J. Am. Acad. Dermatol. 2003, v. 49, p. 145-147.Forschner T., Buchholtz S., Stockfleth E. Current state of vitiligo therapy-evidence-based analysis of the literature. J. Dtsch. Dermatol. Ges. 2007, v. 5 (6), p. 467-475.Lepe V., Moncada B., Castanedo-Cazares J.P. et al. A double-blind randomized trial of 0,1% tacrolimus vs 0,05% clobetasol for the treatment of childhood vitiligo. Arch. Dermatol. 2003, v. 139, p. 581-585.Tjioe M., Vissers W.H., Gerritsen M.J. Topical macrolide immunomodulators: a role in the treatment of vitiligo? MED-LINE. Am. J. Clin. Dermatol. 2006, v. 7 (1), p. 7-12.Bohm M., Gaubitz M., Luger T.A. et al. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three cases. Dermatology. 2003, v. 207, p. 381-385.Druke A., Gambichler T., Altmeyer P. et al. 0,1% tacrolimus ointment in a patient with subacute cutaneous lupus erythematosus. J. Dermatolog. Treat. 2004, v. 15, p. 63-64.Lampropoulos C.E., Sangle S., Harrison P. et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford). 2004, v. 43, p. 1383-1385.Yoshimasu T., Ohtani T., Sakamoto T. et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur. J. Dermatol. 2002, v. 12, p. 50-52.Kanekura T., Yoshii N., Terasaki K. et al. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br. J. Dermatol. 2003, v. 148, p. 353-356.Kreuter A., Gambichler T, Breuckmann F. et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J. Am. Acad. Dermatol. 2004, v. 51 (3), p. 407-410.Uetsu N., Okamoto H., Fujii K. et al. Treatment of chronic actinic dermatitis with tacrolimus ointment. J. Am. Acad. Dermatol. 2002, v. 47, p. 881-884.McCall C.O. Treatment of chronic actinic dermatitis with tacrolimus ointment. J. Am. Acad. Dermatol. 2003, v. 49, p. 775.Suga Y., Hashimoto Y., Matsuba S. et al. Topical tacrolimus for chronic actinic dermatitis. J. Am. Acad. Dermatol. 2002, v. 46, p. 321-323.Abe R., Shimizu T, Tsuji A. et al. Severe refractory chronic actinic dermatitis successfully treated with tacrolimus ointment. Br. J. Dermatol. 2002, v. 147, p. 1273-1275.Ogawa Y., Adachi A., Tomita Y. The successful use of topical tacrolimus treatment for a chronic actinic dermatitis patient with complications of idiopathic leukopenia. J. Dermatol. 2003, v. 30, p. 805-809.Evans A.V., Palmer R.A., Hawk J.L. Erythrodermic chronic actinic dermatitis responding only to topical tacrolimus. Photodermatol Photoimmunol Photomed. 2004, v. 20, p. 59-61.Bohm M., Frieling U., Luger T.A., Bonsmann G. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch. Dermatol. 2003, v. 139, p. 922-924.Kunstfeld R., Kirnbauer R., Stingl G., Karlhofer F.M. Successful treatment of vulvar lichen sclerosus with topical tacrolimus. Arch. Dermatol. 2003, v. 139, p. 850-852.Assmann T., Becker-Wegerich P., Grewe M. et al. Tacrolimus ointment for the treatment of vulvar lichen sclerosus. J. Am. Acad. Dermatol. 2003, v. 48, p. 935-937.Hodgson T.A., Malik F., Hegarty A.M., Porter S.R. Topical tacrolimus: a novel therapeutic intervention for recalcitrant labial pemphigus vulgaris. Eur. J. Dermatol. 2003, v. 13, p. 142-144.Gach J.E., Ilchyshyn A. Beneficial effects of topical tacrolimus on recalcitrant erosions of pemphigus vulgaris. Clin. Exp. Dermatol. 2004, v. 29, p. 271-272.Rabeni E.J., Cunningham N.M. Effective treatment of Hailey-Hailey disease with topical tacrolimus. J. Am. Acad. Dermatol. 2002, v. 47, p. 797-798.Sand C., Thomsen H.K. Topical tacrolimus ointment is an effective therapy for Hailey-Hailey disease. Arch. Dermatol. 2003, v. 139, p. 1401-1402.Umar S.A., Bhattacharjee P., Brodell R.T. Treatment of Hailey-Hailey disease with tacrolimus ointment and clobetasol propionate foam. J. Drugs. Dermatol. 2004, v. 3, p. 200-203.McElwee K.J., Rushton D.H., Trachy R., Oliver R.F. Topical FK506: a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. Br. J. Dermatol. 1997, v. 137, p. 491-497.Freyschmidt-Paul P., Ziegler A., McElwee K.J. et al. Treatment of alopecia areata in C3H/HeJ mice with the topical immunosuppressant FK506 (tacrolimus). Eur. J. Dermatol. 2001, v. 11, p. 405-409.McMillen R., Duvic M. Alopecia areata occurring in sisters after administration of rifampicin. J. Am. Acad. Dermatol. 2001, v. 44, p. 142-143.Harth W., Linse R. Topical tacrolimus in granuloma annulare and necrobiosis lipoidica. Br. J. Dermatol. 2004, v. 150, p. 792-794.Bens G., Boralevi F., Buzenet C., Taieb A. Topical treatment of Netherton's syndrome with tacrolimus ointment without significant systemic absorption. Br. J. Dermatol. 2003, v. 149, p. 224-226.Allen D.M., Esterly N.B. Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. Arch. Dermatol. 2002, v. 138, p. 1259-1260.Chu J., Bradley M., Marinkovich M.P. Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. Arch. Dermatol. 2003, v. 139, p. 813-815.Hollar C.B., Jorizzo J.L. Topical tacrolimus 0,1% ointment for refractory skin disease in dermatomyositis: a pilot study. J. Dermatolog. Treat. 2004, v. 15, p. 35-39.Wollina U. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am. J. Clin. Dermatol. 2007, v. 8 (3), p. 157-173.Rallis E., Korfitis C., Gregoriou S, Rigopoulos D. Assigning new roles to topical tacrolimus. Expert. Opin. Investig. Drugs. 2007, v. 16 (8), p. 1267-1276.Pabby A., An K.P., Laws R.A. Combination therapy of tetracycline and tacrolimus resulting in rapid resolution of steroid-induced periocular rosacea. Cutis. 2003, v. 72, p. 141-142.2005 Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements. URL: <http://www.fda.gov/medwatch/>SAFETY/2005/safety05.htm (Доступность проверена 25.11.2007).Munzenberger P.J., Montejo J.M. Safety oftopical calcineurin inhibitors for the treatment of atopic dermatitis. Pharmacotherapy. 2007, v. 27 (7), p. 1020-1028.Борисенко О.В. Эффективность и соотношение затрат и эффективности применения пимекролимуса и такролимуса при атопическом дерматите: систематический обзор и экономическая оценка. Источник: Garside R., Stein K., Castelnuovo E., Pitt M., Ashcroft D., Dimmock P., Payne L. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. Health Technology Assessment. 2005, v. 9, p. 29.Ellis C.N., Drake L.A., Prendergast M.M. et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J. Am. Acad. Dermatol. 2003, v. 48, p. 553-563.Wollenberg A. et al. Proactive treatment of atopic dermatitis in adults with 0,1% tacrolimus ointment. Allergy. 2008, p. 742-750.Thaci D. et al. Proactive disease management with 0,03% tacrolimus ointment for children with atopic dermatitis: results of randomized, multicentre, comparative study. Br. J. Dermatol. 2008, v. 159, p. 1348-1356.